Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine-Fludarabine-Busulfan vs Fludarabine-Busulfan Conditioning for AML-MR
NCT06297772Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Disease-Free Survival at 2 years. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06297772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297772.